Key result
Higher plasma resistin levels were significantly associated with permanent atrial fibrillation in patients with cardiovascular disease (median 6.90 ng/mL vs. 5.83 ng/mL, P = 0.03).
Why the study?
Atrial fibrillation affects quality of life and prognosis in cardiovascular disease, and resistin plays an important role in inflammatory responses, but its association with permanent AF in these patients required evaluation.
Are elevated blood plasma resistin levels associated with permanent atrial fibrillation in patients with cardiovascular disease?
Observational (n=146)
No
Are elevated blood plasma resistin levels associated with permanent atrial fibrillation in patients with cardiovascular disease?
Effect estimate: β = 0.79 (95% CI 0.08 to 1.51)
Absolute Event Rate: 6.9% vs 5.83%
p-value: p=0.03
Elevated blood plasma resistin levels are independently associated with permanent atrial fibrillation in patients with cardiovascular disease, suggesting a potential role as a biomarker.
May link resistin to permanent AF via inflammation; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Atrial fibrillation (AF) affects quality of life and prognosis of patients with cardiovascular disease. Resistin plays an important role in inflammatory response to internal and external factors. The aim of this study is to evaluate the association between resistin and permanent AF (PAF) in patients with cardiovascular disease. METHODS: In our study, we included 146 patients with cardiovascular disease. Plasma resistin concentrations and demographic characteristics of patients were recorded. The patients were divided in two groups: 118 patients without a history of PAF (NonAF group), and 28 patients with a history of PAF (AF group). Association of resistin with PAF and other variables was examined by parametric and non-parametric tests, and multivariable linear and univariable logistic regression analysis. RESULTS: No differences of demographic characteristics (gender, age and body mass index (BMI)) between two groups were observed (P > 0.05). Higher median levels of resistin were observed in group AF than in group NonAF (6.90 ng/mL vs. 5.83 ng/mL, P = 0.03). Multivariate linear regression analysis (adjusted to gender, age, BMI, hypertension, diabetes mellitus, coronary artery disease, and mitral valve disease) showed that resistin was associated with PAF (β = 0.79, 95% confidence interval (CI): 0.08 to 1.51, P = 0.03). CONCLUSIONS: Our analysis showed that plasma resistin was associated with PAF, and resistin concentration was higher in patients with AF compared to those without AF.
No takes yet. Share an insight, caveat, or question.
Samanidis et al. (2020) conducted an observational in Cardiovascular disease and Atrial Fibrillation (n=146). Blood plasma resistin vs. Patients without permanent atrial fibrillation was evaluated on Association of resistin with permanent atrial fibrillation (β = 0.79, 95% CI 0.08 to 1.51, p=0.03). Higher plasma resistin levels were significantly associated with permanent atrial fibrillation in patients with cardiovascular disease (median 6.90 ng/mL vs. 5.83 ng/mL, P = 0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: